http://www.empr.com/jenny-ko-pharmd/author/936/ Latest articles by Jenny Ko, PharmD from MPR MPR custserv@haymarketmedia.com no National data show that women are more likely to be uninsured, and when they have insurance, can pay premiums up to 84% higher than men who are receiving the same coverage. The Affordable Care Act contains a provision that enforces private insurance companies to make certain preventive services (e.g., mammograms, screenings for cervical cancer, prenatal care, and other services) available without co-pays, co-insurance or deductibles. http://www.empr.com/healthcare-reform-and-womens-health-preventive-services-what-is-now-cost-free-to-the-patient/article/254514/ Tue, 14 Aug 2012 15:31:29 GMT National data show that women are more likely to be uninsured, and when they have insurance, can pay premiums up to 84% higher than men who are receiving the same coverage. The Affordable Care Act contains a provision that enforces private insurance companies to make certain preventive services (e.g., mammograms, screenings for cervical cancer, prenatal care, and other services) available without co-pays, co-insurance or deductibles. MPR Using nano-formulated, lower-dose NSAIDs may provide clinical benefit for relieving mild to moderate acute pain, reported Garen Manvelian, MD, with Iroko Pharmaceuticals, Philadelphia, PA, at the American Pain Society's 31st Annual Scientific Meeting. http://www.empr.com/nano-formulated-naproxen-provides-faster-pain-relief-than-traditional-naproxen/article/241910/ Sat, 19 May 2012 19:00:00 GMT Using nano-formulated, lower-dose NSAIDs may provide clinical benefit for relieving mild to moderate acute pain, reported Garen Manvelian, MD, with Iroko Pharmaceuticals, Philadelphia, PA, at the American Pain Society's 31st Annual Scientific Meeting. MPR At the American Pain Society's 31st Annual Scientific Meeting, study investigators presented data indicating that high dosages of oxymorphone extended-release (ER) appear to be generally well tolerated in patients with chronic noncancer pain. http://www.empr.com/high-doses-of-oxymorphone-extended-release-generally-well-tolerated/article/241909/ Sat, 19 May 2012 18:00:00 GMT At the American Pain Society's 31st Annual Scientific Meeting, study investigators presented data indicating that high dosages of oxymorphone extended-release (ER) appear to be generally well tolerated in patients with chronic noncancer pain. MPR Panadol Advance (paracetamol; fast-absorbing) 1,000mg tablets were more efficacious and demonstrated faster onset and longer duration of pain relief compared with Panadol Advance 500mg, standard paracetamol 650mg, and placebo, reported Yong Yue, MD, from Jean Brown Research, Salt Lake City, UT at the American Pain Society's 31st Annual Scientific Meeting. http://www.empr.com/panadol-advance-provides-faster-pain-relief-in-post-surgical-dental-pain/article/241905/ Sat, 19 May 2012 14:00:00 GMT Panadol Advance (paracetamol; fast-absorbing) 1,000mg tablets were more efficacious and demonstrated faster onset and longer duration of pain relief compared with Panadol Advance 500mg, standard paracetamol 650mg, and placebo, reported Yong Yue, MD, from Jean Brown Research, Salt Lake City, UT at the American Pain Society's 31st Annual Scientific Meeting. MPR Diclofenac sodium 1% gel is well tolerated for up to 1 year for the relief of osteoarthritis (OA) pain in patients both <65 years and ≥65 years of age, according to 12-month data presented at the American Pain Society's 31st Annual Scientific Meeting. http://www.empr.com/diclofenac-sodium-1-gel-safe-for-long-term-treatment-of-osteoarthritis-in-elderly/article/241903/ Sat, 19 May 2012 12:30:00 GMT Diclofenac sodium 1% gel is well tolerated for up to 1 year for the relief of osteoarthritis (OA) pain in patients both <65 years and ≥65 years of age, according to 12-month data presented at the American Pain Society's 31st Annual Scientific Meeting. MPR At the American Pain Society's 31st Annual Scientific Meeting, Jon Levine, MD, PhD discussed recent data showing that kappa-opioids, generally observed to be less effective in providing pain relief than mu-receptor opioids, were not only equally effective in producing pain relief in a female patient population, but were also associated with a reduced incidence of adverse effects and greater overall patient satisfaction. http://www.empr.com/gender-differences-in-pain-management-the-effect-of-sexual-dimorphism/article/241902/ Sat, 19 May 2012 12:00:00 GMT At the American Pain Society's 31st Annual Scientific Meeting, Jon Levine, MD, PhD discussed recent data showing that kappa-opioids, generally observed to be less effective in providing pain relief than mu-receptor opioids, were not only equally effective in producing pain relief in a female patient population, but were also associated with a reduced incidence of adverse effects and greater overall patient satisfaction. MPR Acetaminophen 1,000mg does provide an incremental benefit vs. acetaminophen 650mg, reported Daniel Qi, from McNeil Consumer Healthcare, Fort Washington, PA, at the American Pain Society's 31st Annual Scientific Meeting. http://www.empr.com/acetaminophen-1000mg-provides-incremental-benefit-over-acetaminophen-650mg/article/241791/ Fri, 18 May 2012 16:00:00 GMT Acetaminophen 1,000mg does provide an incremental benefit vs. acetaminophen 650mg, reported Daniel Qi, from McNeil Consumer Healthcare, Fort Washington, PA, at the American Pain Society's 31st Annual Scientific Meeting. MPR Naproxen significantly improved pain relief following arthroscopic surgery and reduced opioid utilization with no evidence of increased risk of adverse events, reported Evan Ekman, MD from Southern Orthopaedic Sports Medicine, Columbia, SC, at the American Pain Society's 31st Annual Scientific Meeting. http://www.empr.com/over-the-counter-naproxen-is-an-effective-opioid-sparing-strategy-for-post-arthroscopy-pain/article/241538/ Thu, 17 May 2012 19:00:00 GMT Naproxen significantly improved pain relief following arthroscopic surgery and reduced opioid utilization with no evidence of increased risk of adverse events, reported Evan Ekman, MD from Southern Orthopaedic Sports Medicine, Columbia, SC, at the American Pain Society's 31st Annual Scientific Meeting. MPR Minimal systemic distribution of topical diclofenac sodium gel resulted in a lower incidence of major or moderate drug-drug interactions associated with oral diclofenac and reduced the risk of drug interaction-related adverse events. Study results were reported by Matthew Wieman, MD, from Endo Pharmaceuticals, John H. Peniston, DO, from Novartis Consumer Health, and colleagues at the American Pain Society's 31st Annual Scientific Meeting. http://www.empr.com/diclofenac-sodium-1-gel-minimizes-drug-drug-interaction-related-adverse-events/article/241537/ Thu, 17 May 2012 18:00:00 GMT Minimal systemic distribution of topical diclofenac sodium gel resulted in a lower incidence of major or moderate drug-drug interactions associated with oral diclofenac and reduced the risk of drug interaction-related adverse events. Study results were reported by Matthew Wieman, MD, from Endo Pharmaceuticals, John H. Peniston, DO, from Novartis Consumer Health, and colleagues at the American Pain Society's 31st Annual Scientific Meeting. MPR Study investigators presented data from the UPLOAD (Understanding Pain & Limitations in OsteoArthritic Disease) study at the American Pain Society's 31st Annual Scientific Meeting demonstrating that hydroxyvitamin D levels <25ng/mL were associated with an increase in osteoarthritis (OA) symptoms and a decreased threshold for pressure pain. http://www.empr.com/vitamin-d-deficiency-associated-with-increased-osteoarthritis-symptoms-and-reduced-pain-threshold/article/241533/ Thu, 17 May 2012 16:00:00 GMT Study investigators presented data from the UPLOAD (Understanding Pain & Limitations in OsteoArthritic Disease) study at the American Pain Society's 31st Annual Scientific Meeting demonstrating that hydroxyvitamin D levels <25ng/mL were associated with an increase in osteoarthritis (OA) symptoms and a decreased threshold for pressure pain. MPR